Literature DB >> 16809444

Pituitary tumor transforming gene overexpression facilitates pituitary tumor development.

Ines Donangelo1, Shiri Gutman, Eva Horvath, Kalman Kovacs, Kolja Wawrowsky, Michael Mount, Shlomo Melmed.   

Abstract

Intrinsic and extrinsic stimuli result in profound pituitary growth changes ranging from hypoplasia to hyperplasia. Pituitary tumor transforming gene (PTTG) abundance correlates with pituitary trophic status. Mice with Pttg inactivation exhibit pituitary hypoplasia, whereas targeted pituitary PTTG overexpression driven by alpha-subunit glycoprotein (alphaGSU) promoter results in focal pituitary hyperplasia. To test the impact of pituitary hyperplasia on tumor development, we crossbred alphaGSU.PTTG with Rb+/- mice, which develop pituitary tumors with high penetrance. Pituitary glands of resulting bitransgenic alphaGSU.PTTGxRb+/- mice were compared with monotransgenic alphaGSU.PTTG, Rb+/-, and wild-type mice. Confocal microscopy showed that PTTG-overexpressing cells have enlarged nuclei and marked redistribution of chromatin, and electron microscopy of alphaGSU.PTTG pituitaries showed enlarged gonadotrophs with prominent Golgi complexes and numerous secretory granules. These morphological findings were even more remarkable in alphaGSU.PTTGxRb+/- pituitaries. Mice from all four genotypes were sequentially imaged by magnetic resonance imaging to evaluate pituitary volume, and glands from alphaGSU.PTTGxRb+/- mice were the largest as early as 2 months of age (P = 0.0003). Cumulative incidence of pituitary tumors visualized by magnetic resonance imaging did not differ between Rb+/- and alphaGSU.PTTGxRb+/- mice. However, anterior lobe tumors determined after necropsy were 3.5 times more frequent in alphaGSU.PTTGxRb+/- than in Rb+/- mice (P = 0.0036), whereas the frequency of intermediate lobe tumors was similar. In summary, alphaGSU.PTTGxRb+/- pituitary glands exhibit enhanced cellular activity, increased volume, and higher prevalence of anterior pituitary tumors, indicating that changes in pituitary PTTG content directly relate to both pituitary trophic status and tumorigenic potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809444     DOI: 10.1210/en.2006-0544

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kolja Wawrowsky; Yuji Tani; Anat Ben-Shlomo; Vladimir Ljubimov; Adam Mamelak; Serguei Bannykh; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2012-10-09

Review 2.  Mouse models of endocrine tumours.

Authors:  Georgette N Jones; Parmeet K Manchanda; Daphne R Pringle; Mei Zhang; Lawrence S Kirschner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

3.  Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage.

Authors:  Ines Donangelo; Song-Guang Ren; Tamar Eigler; Clive Svendsen; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2014-01-30       Impact factor: 5.678

4.  Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.

Authors:  Ning-Ai Liu; Hong Jiang; Anat Ben-Shlomo; Kolja Wawrowsky; Xue-Mo Fan; Shuo Lin; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

5.  Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.

Authors:  Paraskevi Xekouki; Eva Szarek; Petra Bullova; Alessio Giubellino; Martha Quezado; Spyridon A Mastroyannis; Panagiotis Mastorakos; Christopher A Wassif; Margarita Raygada; Nadia Rentia; Louis Dye; Antony Cougnoux; Deloris Koziol; Maria de La Luz Sierra; Charalampos Lyssikatos; Elena Belyavskaya; Carl Malchoff; Jessica Moline; Charis Eng; Louis James Maher; Karel Pacak; Maya Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-02-19       Impact factor: 5.958

Review 6.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

7.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

8.  E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

Authors:  Cuiqi Zhou; Kolja Wawrowsky; Serguei Bannykh; Shiri Gutman; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-10-16

Review 9.  Mitotic chromosomal instability and cancer: mouse modelling of the human disease.

Authors:  Juan-Manuel Schvartzman; Rocio Sotillo; Robert Benezra
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

10.  HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Authors:  Monica Fedele; Orlando Paciello; Davide De Biase; Mario Monaco; Gennaro Chiappetta; Michela Vitiello; Antonio Barbieri; Domenica Rea; Antonio Luciano; Serenella Papparella; Claudio Arra; Alfredo Fusco
Journal:  Cell Cycle       Date:  2018-01-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.